Stock WLLW WILLOW BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Willow Biosciences Inc. Canadian Securities Exchange

Equities

WLLW

CA97111B4047

Delayed Canadian Securities Exchange
Other stock markets
 		5-day change 1st Jan Change
- CAD -.--% Intraday chart for Willow Biosciences Inc. -.--% -.--%
05-30 Willow Biosciences Signs Multi-Product Development, Licensing Partnership With Laurus Lab MT
05-30 Willow Biosciences Brief: Announcing Multi-product Development and Licensing Partnership With Laurus Lab MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Willow Biosciences Signs Multi-Product Development, Licensing Partnership With Laurus Lab
MT
Willow Biosciences Brief: Announcing Multi-product Development and Licensing Partnership With Laurus Lab
MT
WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS
AQ
Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results
MT
Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024
CI
Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Willow Biosciences Narrows 2023 Loss YOY
MT
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
AQ
Willow Biosciences Announces Second Strategic Investment From Kalsec
MT
Willow Biosciences Secures Strategic Investment From Kalsec to Develop Natural Food Ingredient
MT
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.
CI
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer
MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market
CI
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
AQ
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally
CI
Willow Biosciences Announces Collaboration With Enterin
MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients
CI
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
AQ
Willow Biosciences Highlights Growth Plans for 2024, Provides 2023 Highlights
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. WLLW Stock
  4. WLLW Stock
  5. News Willow Biosciences Inc.